Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of a Quadrivalent Influenza Virus Subunit Vaccine in Subjects Aged 6-35 Months
NCT05645900Phase 3Completed
- Sponsor
- Ab&B Bio-tech Co., Ltd.
- Start
- Feb 2023
- Primary completion
- Oct 2023
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in influenza (3 arms), sponsored by Ab&B Bio-tech Co., Ltd. Primary endpoints: Adverse Events at 30 minutes, Serious Adverse Events at 6 months and 3 more. Started Feb 2023; status: completed.
02
Conditions
influenza
Beyond the preview
Go deeper on NCT05645900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05645900.